solifenacin succinate has been researched along with Amentia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomes, T; Herschorn, S; Jarvi, K; Juurlink, D; Matta, R; Nam, RK | 1 |
| Dantas, LP; Forte, ARCC; Lessa, PHC; Lima, BC; Patrocínio, MCA; Sousa, CNS; Vasconcelos, EC; Vasconcelos, SMM; Vieira, RF | 1 |
| Berr, C; Droupy, S; Faillie, JL; Huguet, H; Malcher, MF; Mura, T; Serrand, C; Ziad, A | 1 |
| Panicker, JN; Richardson, K; Welk, B | 1 |
2 review(s) available for solifenacin succinate and Amentia
| Article | Year |
|---|---|
Treatment of bladder dysfunction with solifenacin: is there a risk of dementia or cognitive impairment?
Topics: Aged; Cognitive Dysfunction; Dementia; Humans; Solifenacin Succinate; Urinary Bladder; Urinary Bladder, Overactive | 2022 |
The cognitive effect of anticholinergics for patients with overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Cholinergic Antagonists; Cognition; Cognitive Dysfunction; Dementia; Humans; Mandelic Acids; Prodromal Symptoms; Pyrrolidines; Risk Assessment; Risk Factors; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive | 2021 |
2 other study(ies) available for solifenacin succinate and Amentia
| Article | Year |
|---|---|
Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
Topics: Aged; Canada; Case-Control Studies; Dementia; Humans; Muscarinic Antagonists; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive | 2022 |
Dementia Associated with Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cholinergic Antagonists; Dementia; Humans; Muscarinic Antagonists; Solifenacin Succinate; Urinary Bladder, Overactive | 2022 |